Tisagenlecleucel
Approved · EMAAlso known as Adoptive immunotherapy agent CTL019, CAR.CD19-Redirected T cells, Kymriah, Tisagenlecleucel-T+1 more
Adoptive immunotherapy agent CTL019, CAR.CD19-Redirected T cells, Kymriah, Tisagenlecleucel-T, tisagenlecleusel.
Recent clinical, regulatory, research and industry developments relating to this drug.
Chimeric Antigen Receptor (CAR)-T Cell Therapy for Patients With Hematologic Malignancies
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel.
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Pharmacology & targets
Known molecular targets and mechanisms supported by curated pharmacology databases.
Regulatory timeline
The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.
Indication: Kymriah is indicated for the treatment of: • Paediatric and young adult patients up to and including 25 years of age with B cell acute lymphoblastic leukaemia (ALL) that is… Show full indicationShow less
Kymriah is indicated for the treatment of: • Paediatric and young adult patients up to and including 25 years of age with B cell acute lymphoblastic leukaemia (ALL) that is refractory, in relapse post transplant or in second or later relapse. • Adult patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) after two or more lines of systemic therapy. • Adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.
Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes2
Journals, researchers & institutions
- The New England journal of medicine2
- Blood1
- Journal of hematology & oncology1
- Grupp SA2
- Salles G2
- Ackermann J1
- Anak Ö1
- Andreadis C1
- Awasthi R1
- Ayuk F1
- Bachanova V1
- Abramson Cancer Center1
- and German Cancer Research Center1
- Center for Childhood Cancer Research and Cancer Immunotherapy Program1
- Children's Hospital of Philadelphia1
- Institute for Medical Informatics1
- Laboratory for Translational Cancer Immunology1
Related diseases
Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Acts on the same molecular target as Tisagenlecleucel, with 8 overlapping disease areas.
Studied across 3 of the same disease areas as Tisagenlecleucel in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials
- Regulatory event sources are credited in the Regulatory Timeline above.